## MOH: Molina Healthcare Inc - XLV: Healthcare

### Executive Summary

No thesis match: PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($146.08)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 1, Bearish: 0)

**1. Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Molina Healthcare, Inc. (MOH) and Encourages Stockholders to Learn More About the Investigation**
- Source: Fox 59 | 20251209T160950 | Neutral | Relevance: 99%
- Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Molina Healthcare, Inc. (MOH) regarding potential corporate wrongdoing by its officers and/or directors. The firm is encouraging stockholders who purchased Molina securities prior to February 5, 2025, and still hold them, to engage with the investigation to explore potential claims. The investigation aims to determine if Molina and its leadership acted improperly, potentially harming investors.

**2. Bronstein, Gewirtz & Grossman, LLC Encourages Molina Healthcare, Inc. (MOH) Investors to Inquire about Securities Investigation**
- Source: WANE 15 | 20251207T160850 | Neutral | Relevance: 99%
-  Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Molina Healthcare, Inc. (NYSE: MOH) securities. The investigation focuses on whether Molina and its officers/directors engaged in corporate wrongdoing. Investors who bought Molina securities before February 5, 2025, and still hold them, are encouraged to contact the firm for more information regarding this securities investigation.

**3. Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Molina Healthcare, Inc. (MOH) and Encourages Stockholders to Learn More About the Investigation**
- Source: Eyewitness News (WEHT/WTVW) | 20251209T160943 | Neutral | Relevance: 99%
-  Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Molina Healthcare, Inc. (MOH) to determine if the company and its officers engaged in corporate wrongdoing. The firm is encouraging stockholders who purchased Molina securities before February 5, 2025, and still hold them, to contact them to learn more about the investigation and potentially assist. The firm represents investors on a contingency fee basis in securities fraud class actions and shareholder derivative suits.

**4. The MolinaCares Accord Commits $200,000 to Fund Maternal Health Navigators in Mississippi**
- Source: Business Wire | 20251209T130246 | Bullish | Relevance: 99%
-  The MolinaCares Accord and Molina Healthcare of Mississippi announced a $200,000 grant to Magnolia Medical Foundation over four years. This funding will support maternal health navigators and operations at Foundation clinics from 2026 to 2028, aiming to expand access to maternal healthcare in Mississippi. The initiative addresses the state's high number of maternity care deserts and promotes critical care for underserved populations.

**5. Bronstein, Gewirtz & Grossman, LLC Encourages Molina Healthcare, Inc. (MOH) Investors to Inquire about Securities Investigation**
- Source: KTSM 9 News | 20251207T160753 | Neutral | Relevance: 99%
-  Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Molina Healthcare, Inc. (NYSE: MOH) securities. The firm encourages investors who bought Molina securities before February 5, 2025, and still hold them, to contact them to assist in an investigation into alleged corporate wrongdoing by the company's officers and/or directors. This investigation aims to determine if Molina engaged in such wrongdoing.

### Analyst Activity

**Target Signal:** VERY_BEARISH (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-12 | Wells Fargo | $165 | $231 | -29% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-12 | Wells Fargo | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 8 ($0.44M) |
| Sells | 1 ($0.05M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 61.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 11.9% (+0.1%)
- Capital World Invest: 9.5% (-2.0%)
- Blackrock Inc.: 8.4% (-3.9%)
- Price (T.Rowe) Assoc: 6.5% (+58.8%)
- AQR Capital Manageme: 5.4% (+217.0%)

### Key Risks

1. Elevated short interest (10.0%): bears positioning against stock.
2. Long-term trend broken: trading 33.4% below SMA200.
3. Falling knife pattern: rapid decline without stabilization, catch risk elevated.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +2.8% over 5 days suggests accumulation.

### Fundamentals

Analyst sentiment negative (1 target cuts vs 0 raises). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $8.5B |
| Beta | 0.52 |
| 52W Range | $133.40 - $359.97 |
| Short Interest | 10.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -0.62 |
| Forward P/E | 11.1 |
| Current P/E | 11.1 |
| YoY Growth | -0.4% |
| EPS Direction | FALLING |

### Technicals

MRS_10 strengthening from 1.1% to 3.9% (+2.8% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (3.0-6.0%), cross-sectional ranking at 87th percentile. MRS_5 at 2.5% confirms short-term momentum alignment. Outperforming sector by 8.4pp, stock-specific strength. Below SMA200 (0.67x), long-term trend not supportive. MACD histogram positive (2.93), confirming momentum. RSI neutral at 57.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 3.91% (CS: 88) | Strong |
| RSI_14 | 56.9 | Neutral |
| MACD Histogram | 2.93 | Bullish |
| vs SMA20 | 1.083x | Above |
| vs SMA50 | 0.953x | Below |
| vs SMA200 | 0.666x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $156.88
- **Stop Loss:** $146.08 (6.9% risk)
- **Target:** $167.68 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 27
- **Position Value:** $4,235.76
- **Portfolio %:** 4.24%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not invertedâ€”indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-04 (Est: $0.64)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.89 | $1.84 | -52.7% |
| 2025Q2 | $5.53 | $5.48 | -0.9% |
| 2025Q1 | $5.96 | $6.08 | +2.0% |
| 2024Q4 | $5.88 | $5.05 | -14.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*